ESR1 and neoplasm: Endocrine therapy represents the first line pharmacological regimen for ERα + BCs, although in most cases it results are very positive for the patient, it is ineffective in about 30% of cases, due to intrinsic and acquired resistance of cancer cells to the antiestrogenic activity of the drugs used, resulting in severe consequences due to tumor relapse and metastasis.